Evidence map›Paper›PMID 41208953›Full record

ArticleFrontiers in immunology2025

rBCG-LTAK63 enhances protection against tuberculosis by inducing autophagy and circadian gene regulation.

Lázaro M Marques-Neto, Monalisa M Trentini, Ana Carolina R Moreno, Silas F Eto, Ana Carolina O Carvalho, Almiro P S Neto, Murilo S Amaral, André G C Martins, André N A Gonçalves, Ana Marisa Chudzinski-Tavassi and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lázaro M Marques-NetoLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Monalisa M TrentiniLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Ana Carolina R MorenoLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Silas F EtoCenter of Excellence in New Target Discovery (CENTD), Instituto Butantan, São Paulo, Brazil.
Ana Carolina O CarvalhoLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Almiro P S NetoLaboratório de Medicina e Saúde Pública de Precisão (MeSP2), Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ-BA), Salvador, Brazil.
Murilo S AmaralLaboratório de Ciclo Celular, Instituto Butantan, São Paulo, Brazil.
André G C MartinsDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences. University of São Paulo, São Paulo, Brazil.
André N A GonçalvesMicromanufacturing Laboratory, Institute for Technological Research, São Paulo, Brazil.
Ana Marisa Chudzinski-TavassiCenter of Excellence in New Target Discovery (CENTD), Instituto Butantan, São Paulo, Brazil.
Alex I KannoLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Aldo TagliabueShenzhen Institutes of Advanced Technology (SIAT), Shenzhen-Guangdong, China.
Diana BoraschiShenzhen Institutes of Advanced Technology (SIAT), Shenzhen-Guangdong, China.
Sergio Verjovski-AlmeidaLaboratório de Ciclo Celular, Instituto Butantan, São Paulo, Brazil.
Helder NakayaDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences. University of São Paulo, São Paulo, Brazil.
Leonardo P FariasLaboratório de Medicina e Saúde Pública de Precisão (MeSP2), Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ-BA), Salvador, Brazil.
Pablo I P RamosCentro de Integração de Dados e Conhecimentos para Saúde (CIDACS), Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ-BA), Salvador, Brazil.
Luciana C C LeiteLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) remains a global public health challenge, with the current BCG vaccine providing limited efficacy in adults, and available treatments being lengthy and debilitating. To overcome these challenges, we have previously developed a recombinant BCG strain expressing the detoxified

Indexed as

AutophagyBCG VaccineCircadian RhythmEscherichia coli ProteinsMycobacterium tuberculosisTuberculosisAnimalsDisease Models, AnimalFemaleGene Expression RegulationImmunity, InnateLungMiceMice, Inbred C57BLBCG VaccineEscherichia coli Proteinsadjuvantrecombinant BCGtranscriptometuberculosisvaccine

Identifiers

PMID41208953
PMCPMC12592191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.